Speech and voice response to levodopa in late-stage Parkinson’s Disease patients: report from an acute levodopa challenge
Objective: to assess the change of speech and voice after an acute L-dopa challenge in late-stage Parkinson’s disease (LSPD). Background: PD patients are classically affected…Dextrometorphan/quinidine in Atypical Parkinsonisms and Huntington Disease
Objective: to determine whether Dextrometorphan/quinidine (DMQ) is effective in the treatment of PBA, AG or bulbar symptoms in corticobasal syndrome (CBS), multiple system atrophy (MSA),…Use of pimavanserin in patients with Parkinson’s disease psychosis: Subgroup analysis of efficacy and safety in patients with and without cognitive impairment
Objective: A planned subgroup analysis of a phase 3 study was performed to evaluate the efficacy and safety of pimavanserin (PIM) in Parkinson’s disease psychosis…Is there a significant relationship between weight loss and prevalence of side effects of Parkinsonian medication? A retrospective, single-centre analysis, South Wales, UK.
Objective: To investigate if there is a significant relationship between weight loss in persons with Parkinson’s disease and side-effect incidence, and if so to what…Development of a Clinician-reported Screening Tool to Identify Patients with Parkinson’s disease inadequately controlled on oral medications
Objective: To identify key clinical indicators for Parkinson disease (PD) patients inadequately controlled with oral medications or eligible for device-aided treatments. Background: Identifying patients with…Specific Bdnf variants are associated with suboptimal response to levodopa but not to other dopaminergic medications or deep brain stimulation in Parkinson’s disease
Objective: We examined the impact of rs6265 and other brain-derived neurotrophic factor (Bdnf) variants in two subject cohorts: 1) early-stage Parkinson’s disease (PD) subjects from…Risk of Parkinson’s disease in zolpidem user: A systematic review and meta-analysis
Objective: To explore the association between zolpidem use and risk of Parkinson's disorder. Background: Zolpidem is commonly prescribed for the treatment of sleep disorder. Epidemiological…Treatment of Parkinson’s disease psychosis–a systematic review of RCTs
Objective: An SLR was conducted to assess the evidence from RCTs supporting the safety and efficacy of Parkinson’s disease psychosis (PDP) treatments. Background: PDP is…Huntington’s Disease Regulatory Science Consortium (HD-RSC): Enabling Pathways to Effective Treatments Through Regulatory Science and Innovation
Objective: To establish a broad-based consortium, the Huntington’s Disease Regulatory Science Consortium (HD-RSC), which will advance disease specific data standards and drug development tools, as…Levodopa responsiveness in Parkinson’s disease is significantly impaired in those with diabetes and increased vascular risk.
Objective: To define variation in L-dopa response in recent onset PD. Background: L-Dopa responsiveness is a defining feature of Parkinson’s disease (PD), but the degree…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 36
- Next Page »